Physician profile
Rubylynn Basilio
NPI 1487387593
$3,999.37
in general payments reported to CMS, 2019-2025
36 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $617 · 2023: $974 · 2024: $941 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,976 · Education: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,976.29 |
| Education | $406.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $634.58 | 2022-2025 | Lynparza, Enhertu, Imfinzi |
| Daiichi Sankyo INC. | $592.31 | 2022-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $407.99 | 2023-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $406.66 | 2022-2025 | Jakafi |
| Abbvie INC. | $233.48 | 2022-2025 | |
| Glaxosmithkline, LLC. | $151.14 | 2025 | Ojjaara |
| Astellas Pharma US INC | $148.98 | 2022 | |
| Seagen INC. | $111.91 | 2023 | Adcetris |
| Karyopharm Therapeutics INC. | $110.70 | 2022-2025 | Xpovio |
| Janssen Biotech, INC. | $99.35 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $90.30 | 2023 | |
| Novartis Pharmaceuticals Corporation | $88.11 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.24 | 2023-2025 | Fruzaqla, Alunbrig, Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $85.60 | 2022-2025 | |
| Tempus Ai, INC | $82.69 | 2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $73.44 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $68.07 | 2022-2023 | Blincyto, Kyprolis |
| Merck Sharp & Dohme LLC | $60.73 | 2024-2025 | Keytruda, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $54.21 | 2023-2025 | Libtayo |
| Adaptive Biotechnologies Corporation | $45.50 | 2025 | Clonoseq |
| Beone Medicines USA, INC. | $41.95 | 2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $35.75 | 2025 | Ultomiris |
| G1 Therapeutics, INC. | $29.36 | 2023 | Cosela |
| Acrotech Biopharma INC. | $29.19 | 2024 | Beleodaq |
| Geron Corporation | $29.13 | 2025 | Rytelo |
| Genzyme Corporation | $23.31 | 2025 | |
| Genentech USA, INC. | $21.08 | 2025 | Itovebi |
| Eisai INC. | $18.42 | 2024 | |
| Pharmaessentia USA Corporation | $18.39 | 2025 | Besremi |
| Legend Biotech USA INC. | $18.06 | 2025 | Carvykti |
| Alnylam Pharmaceuticals INC. | $17.71 | 2025 | Givlaari |
| Beigene USA, INC. | $17.42 | 2024 | Brukinsa |
| Agios Pharmaceuticals, INC. | $17.17 | 2025 | Pyrukynd |
| Sobi, INC | $16.72 | 2025 | |
| Coherus Oncology, INC. | $16.72 | 2023 | |
| Syndax Pharmaceuticals, INC. | $16.00 | 2025 | Niktimvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubylynn Basilio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.